GeneLink Featured at WallStreetCorner
November 17, 2003

MARGATE, NJ--(BUSINESS WIRE)—November 17, 2003-- GeneLink BioSciences, Inc. (OTCBB:GNLK) announced it has been featured in a profile posted as a Special Situation at www.WallStreetCorner.com

The editors' introduction: "GeneLink's Nutragenetics Profile™ & Dermagenetics™ DNA profile assessments are powerful new tests. They are designed to help companies create & deliver health, beauty, & wellness products & regimens that are ultimately more effective -- because they can scientifically target an individual's specific needs. -- GeneLink is an attractive growth situation with substantial appreciation potential. It is emerging from its R&D & startup phases, & is beginning to establish licensing arrangements with major corporations that should propel it, in our opinion, into a very profitable operation."

In their conclusion, they say: "We like the significant progress GeneLink has made. We particularly like the fact that GeneLink's patents pending profile assessments are the basis for such remarkable marketing capability, & that John DePhillipo, the company's CEO, is establishing relationships with major players in the key industries that can best utilize GeneLink's technology. -- We suggest that you seriously look into this emerging situation. In our opinion, it has exceptional long-term appreciation potential. We feel it's somewhat like Intel, Microsoft, Xerox, or IBM probably was when they were at the same age as GeneLink."

About GeneLink: GeneLink BioSciences, Inc. (www.genelink.info) since 1994, developed the World's First Family Centered DNA Bank and Hereditary Genetic Information Service. With recent breakthroughs, GeneLink is a pioneer and leading provider of DNA tests created to facilitate “genetically guided" health, beauty and wellness products. The company both markets and licenses its proprietary tests to the $1.4 trillion cosmetics, nutritional supplement and healthcare industries.

About WallStreetCorner: Formed five years ago as a venue for the Conservative Speculator newsletter, published since 1987, WallStreetCorner -- including Conservative Speculator and Oakley's "Stock Pick," "Opinion," and "Comment" editorial columns -- is now regularly read by investors in 70 countries.

This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE: GeneLink BioSciences, Inc.